Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Opioid use disorder (OUD) causes the death of nearly 130 Americans daily. It is evident that new avenues for treatment are needed. To this end, studies have reported that ‘satiety’ agents such as the glucagon-like peptide-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), decreases responding for addictive drugs such as cocaine, nicotine, alcohol, and oxycodone, but no work has been done with heroin. In this study, we used a reward devaluation model in which rats avoid ingesting a saccharin solution that predicts drug availability to test the effects of 2.4 μg/kg Ex-4 on responding for a natural reward cue (i.e., saccharin) and on cue- and drug-induced heroin seeking. The results showed that treatment with Ex-4 during the 16-day abstinence period and on the test day decreased cue-induced heroin seeking. Drug-induced heroin seeking also was reduced by Ex-4, but only when using a 1 h, but not a 6 h, pretreatment time. Treatment with Ex-4 did not alter intake of the saccharin cue when the drug was on board, but a history of treatment with Ex-4 increased acceptance of the saccharin cue in later extinction trials. Finally, treatment with Ex-4 did not alter body weight, but was associated with increased Orexin 1 receptor (OX1) mRNA expression in the nucleus accumbens shell. Taken together, these findings are the first to show that treatment with a GLP-1R agonist can reduce both cue-induced seeking and drug-induced reinstatement of heroin seeking. As such, a GLP-1R agonist may serve as an effective treatment for OUD in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Drug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Dissecting components of reward: ‘liking’, ‘wanting’, and learning
Berridge, K. C., Robinson, T. E., & Aldridge, J. W. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.014 · Cited by 1,942
Release from prison–a high risk of death for former inmates
Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa064115 · Cited by 1,684
A role for lateral hypothalamic orexin neurons in reward seeking
Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005) · Nature · doi:10.1038/nature04071 · Cited by 1,311 · cited 1×
“Orexins increase food intake, but its modulatory role also has been extended to nonfeeding reward-related processes such as addiction (de Lecea et al., 1998; Sweet et al., 1999; Harris et al., 2005; James et al., 2017).”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Fos Expression in Orexin Neurons Varies with Behavioral State
Estabrooke, I. V., McCarthy, M. T., Ko, E., Chou, T. C., Chemelli, R. M., Yanagisawa, M., Saper, C. B., & Scammell, T. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01656.2001 · Cited by 654
Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior
Boutrel, B., Kenny, P. J., Specio, S. E., Martin-Fardon, R., Markou, A., Koob, G. F., & de Lecea, L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507480102 · Cited by 520
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“Indeed, GLP-1 producing neurons in the NTS project to the NAc (Alhadeff et al., 2012).”
Background
Cited by
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
Effects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
Qeadan, F., McCunn, A., & Tingey, B. (2025) · Addiction · doi:10.1111/add.16679 · Cited by 90
Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1063033 · Cited by 80
“When considering heroin, Ex4 attenuates withdrawal symptoms during heroin abstinence and diminishes heroin-seeking in male rats (Douton et al., 2021).”
BackgroundChiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Metadata
- Authors
- Douton, J. E., Augusto, C., Stoltzfus, B., Carkaci-Salli, N., Vrana, K. E., & Grigson, P. S.
- Venue
- Behavioural Pharmacology
- Published
- 2020-11-20
- Volume
- 32
- Issue
- 4
- Pages
- 265-277
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W3108456353
- Cited by
- 60
- References
- 21
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats. https://app.cochat.ai/papers/10.1097/fbp.0000000000000609
- The paper
- Douton, J. E., Augusto, C., Stoltzfus, B., Carkaci-Salli, N., Vrana, K. E., & Grigson, P. S. (2021). Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.